The Supreme Court appeared divided Monday on the constitutionality of the PTO’s patent re-examination process of inter partes review — in a debate with wide implications for drugmakers on whether patents are considered private property and if they can only be invalidated through a trial by jury.
Source: Drug Industry Daily